NASDAQ:MTFB - Motif Stock Price, Price Target & More

$9.90 -1.05 (-9.59 %)
(As of 04/26/2018 01:18 AM ET)
Previous Close$10.95
Today's Range$9.90 - $10.10
52-Week Range$6.84 - $13.75
Volume1,200 shs
Average Volume2,714 shs
Market Capitalization$2.15 billion
P/E Ratio-52.11
Dividend YieldN/A
Beta0.19

About Motif (NASDAQ:MTFB)

Motif logoMotif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

Receive MTFB News and Ratings via Email

Sign-up to receive the latest news and ratings for MTFB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MTFB
CUSIPN/A
Phone212-210-6248

Debt

Debt-to-Equity Ratio-1.58%
Current Ratio0.96%
Quick Ratio0.96%

Price-To-Earnings

Trailing P/E Ratio-52.11
Forward P/E Ratio-3.64
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.05) per share
Price / Book-198.00

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees6
Outstanding Shares196,210,000

How to Become a New Pot Stock Millionaire

Motif (NASDAQ:MTFB) Frequently Asked Questions

What is Motif's stock symbol?

Motif trades on the NASDAQ under the ticker symbol "MTFB."

When is Motif's next earnings date?

Motif is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Motif.

What price target have analysts set for MTFB?

5 Wall Street analysts have issued 1 year price objectives for Motif's shares. Their predictions range from $7.00 to $32.00. On average, they expect Motif's share price to reach $19.50 in the next twelve months. View Analyst Ratings for Motif.

What are Wall Street analysts saying about Motif stock?

Here are some recent quotes from research analysts about Motif stock:
  • 1. HC Wainwright analysts commented, "Approaches; ECCMID Presentations; Reiterate Buy Stock Data 04/18/2018 Price $10.95 Exchange NASDAQ Price Target $32.00 52-Week High $13.75 52-Week Low $6.84 Enterprise Value (M) $122.3 Market Cap (M) $145 Public Market Float (M) 3.4 Shares Outstanding (M) 13.2 3 Month Avg Volume 2,389 Short Interest (M) 0.00 Balance Sheet Metrics Cash (M) $22.7 Total Debt (M) $0.0 Total Cash/Share $1.72 Book Value/Share $(0.68) EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (1.21) (1.71)A (0.82) 2Q (1.40) (1.19)A (0.76) 3Q NA NA (0.72) 4Q NA NA (0.72) FY (6.92) (4.01) (3.01) Company reports semi-annually; select historical quarterly financial data available from prospectuses. 14 12 10 8 6 APR-17 AUG-17 DEC-17 APR-18 0.12 0.1 0.08 0.06 0.04 0.02 0 Vol. (mil) Price New Drug Application submission completion this quarter." (4/19/2018)
  • 2. WBB Securities analysts commented, "We believe there is a critical need for novel antibiotics. Based on the clinical data provided through Phase 3 studies REVIVE-1 and REVIVE-2, iclaprim has a high probability of obtaining FDA approval. However, success for MTFB is not just manifest through clinical proof, but also through negotiating the vagaries of reimbursement, gaining clinician acceptance, hospital inclusion and inclusion in the overall patient care paradigm. Additionally, we remain concerned about the resourcing path regarding the future of iclaprim. We are therefore initiating our coverage of MTFB with a Sell rating and a 12- month price target of $7.00." (12/29/2017)

Who are some of Motif's key competitors?

Who are Motif's key executives?

Motif's management team includes the folowing people:
  • Mr. Graham George Lumsden, CEO & Exec. Director (Age 58)
  • Mr. Jonathan E. Gold, Interim CFO, Strategic Financial Consultant & Non-Exec. Director (Age 45)
  • Mr. Robert Joseph Bertoldi, Exec. Director (Age 64)
  • Dr. David B. Huang M.D., Ph.D., MBA, J.D., Chief Medical Officer (Age 43)
  • Mr. Robert Dickey IV, Advisor (Age 62)

When did Motif IPO?

(MTFB) raised $17 million in an initial public offering on Friday, November 18th 2016. The company issued 2,400,000 shares at $6.98 per share. H.C. Wainwright & Co. served as the underwriter for the IPO.

Has Motif been receiving favorable news coverage?

News coverage about MTFB stock has been trending somewhat positive on Thursday, according to Accern. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Motif earned a daily sentiment score of 0.11 on Accern's scale. They also gave media headlines about the company an impact score of 45.97 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Motif?

Shares of MTFB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Motif's stock price today?

One share of MTFB stock can currently be purchased for approximately $9.90.

How big of a company is Motif?

Motif has a market capitalization of $2.15 billion. The company earns $-44,810,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Motif employs 6 workers across the globe.

How can I contact Motif?

Motif's mailing address is 125 Park Avenue 25th Floor, New York NY, 10011. The company can be reached via phone at 212-210-6248 or via email at [email protected]


MarketBeat Community Rating for Motif (MTFB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  155
MarketBeat's community ratings are surveys of what our community members think about Motif and other stocks. Vote "Outperform" if you believe MTFB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTFB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Motif (NASDAQ:MTFB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Motif in the last 12 months. Their average twelve-month price target is $19.50, suggesting that the stock has a possible upside of 96.97%. The high price target for MTFB is $32.00 and the low price target for MTFB is $7.00. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldBuyBuyBuy
Consensus Rating Score: 2.402.502.503.00
Ratings Breakdown: 1 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $19.50$21.3333$21.3333$28.50
Price Target Upside: 96.97% upside107.12% upside107.12% upside160.65% upside

Motif (NASDAQ:MTFB) Consensus Price Target History

Price Target History for Motif (NASDAQ:MTFB)

Motif (NASDAQ:MTFB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2018HC WainwrightReiterated RatingBuy$32.00HighView Rating Details
4/16/2018Northland SecuritiesInitiated CoverageOutperformLowView Rating Details
3/29/2018GabelliReiterated RatingHoldHighView Rating Details
12/29/2017WBB SecuritiesInitiated CoverageSell$7.00LowView Rating Details
12/22/2017Seaport Global SecuritiesReiterated RatingBuyHighView Rating Details
4/24/2017Rodman & RenshawBoost Price TargetBuy -> Buy$16.00 -> $25.00LowView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Dividends

Motif (NASDAQ:MTFB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Motif (NASDAQ MTFB) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 0.56%
Insider Trading History for Motif (NASDAQ:MTFB)

Motif (NASDAQ MTFB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Motif (NASDAQ MTFB) News Headlines

Source:
DateHeadline
MTFB: Initiates NDA Submission for IclaprimMTFB: Initiates NDA Submission for Iclaprim
finance.yahoo.com - April 25 at 4:32 PM
MTFB. I agree withMTFB. I agree with
www.lse.co.uk - April 21 at 9:27 AM
HC Wainwright Reiterates "Buy" Rating for Motif (MTFB)HC Wainwright Reiterates "Buy" Rating for Motif (MTFB)
www.americanbankingnews.com - April 19 at 10:01 AM
Motif Bio Announces New Iclaprim Data being Presented at ECCMID 2018Motif Bio Announces New Iclaprim Data being Presented at ECCMID 2018
feeds.benzinga.com - April 19 at 3:48 AM
Posting of UK Annual Report and Accounts & Notice of AGMPosting of UK Annual Report and Accounts & Notice of AGM
finance.yahoo.com - April 17 at 9:55 AM
Motif (MTFB) Coverage Initiated at Northland SecuritiesMotif (MTFB) Coverage Initiated at Northland Securities
www.americanbankingnews.com - April 16 at 7:39 AM
Gabelli Weighs in on Motifs FY2018 Earnings (MTFB)Gabelli Weighs in on Motif's FY2018 Earnings (MTFB)
www.americanbankingnews.com - April 13 at 9:22 AM
Motif (MTFB) Given a $25.00 Price Target at HC WainwrightMotif (MTFB) Given a $25.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 11 at 11:52 PM
Motif Bio Reports Fiscal Year 2017 ResultsMotif Bio Reports Fiscal Year 2017 Results
finance.yahoo.com - April 10 at 10:00 AM
Motif Bio Initiates NDA Rolling Submission for Iclaprim and Provides Business UpdateMotif Bio Initiates NDA Rolling Submission for Iclaprim and Provides Business Update
finance.yahoo.com - April 3 at 9:55 AM
Motif Bio plc - (MTFB) Receives Consensus Rating of "Hold" from AnalystsMotif Bio plc - (MTFB) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 3 at 9:39 AM
Gabelli Reaffirms "Hold" Rating for Motif Bio (MTFB)Gabelli Reaffirms "Hold" Rating for Motif Bio (MTFB)
www.americanbankingnews.com - April 3 at 7:49 AM
 Motif Bio plc - (MTFB) Given Average Rating of "Strong Buy" by Analysts Motif Bio plc - (MTFB) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - March 21 at 10:36 AM
Motif Bio Update on NDA Submission for IclaprimMotif Bio Update on NDA Submission for Iclaprim
finance.yahoo.com - March 20 at 9:48 AM
Is It Too Late To Buy Motif Bio plc (NASDAQ:MTFB)?Is It Too Late To Buy Motif Bio plc (NASDAQ:MTFB)?
finance.yahoo.com - March 20 at 9:48 AM
Zacks: Brokerages Expect Motif Bio plc - (MTFB) Will Post Earnings of -$0.96 Per ShareZacks: Brokerages Expect Motif Bio plc - (MTFB) Will Post Earnings of -$0.96 Per Share
www.americanbankingnews.com - March 19 at 11:20 PM
Zacks: Analysts Set $28.67 Target Price for Motif Bio plc - (MTFB)Zacks: Analysts Set $28.67 Target Price for Motif Bio plc - (MTFB)
www.americanbankingnews.com - March 6 at 9:42 AM
Motif Bio plc - (MTFB) Expected to Post Earnings of -$1.15 Per ShareMotif Bio plc - (MTFB) Expected to Post Earnings of -$1.15 Per Share
www.americanbankingnews.com - March 2 at 7:26 PM
Motif Bio to Present Iclaprim Data at ECCMID 2018Motif Bio to Present Iclaprim Data at ECCMID 2018
finance.yahoo.com - February 21 at 9:44 AM
 Motif Bio plc - (MTFB) Given $28.67 Consensus Price Target by Brokerages Motif Bio plc - (MTFB) Given $28.67 Consensus Price Target by Brokerages
www.americanbankingnews.com - February 18 at 5:24 AM
Motif Bio (MTFB) Rating Increased to Sell at ValuEngineMotif Bio (MTFB) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - February 4 at 9:14 PM
Zacks: Motif Bio plc - (MTFB) Receives Average Recommendation of "Strong Buy" from AnalystsZacks: Motif Bio plc - (MTFB) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - February 3 at 1:34 PM
MTFB: REVIVE-1 Results Published in Clinical Infectious DiseasesMTFB: REVIVE-1 Results Published in Clinical Infectious Diseases
finance.yahoo.com - February 1 at 4:31 PM
Motif Bio Receives Award from Cystic Fibrosis FoundationMotif Bio Receives Award from Cystic Fibrosis Foundation
finance.yahoo.com - January 16 at 9:09 AM
Zacks: Brokerages Anticipate Motif Bio plc - (MTFB) to Announce -$0.96 Earnings Per ShareZacks: Brokerages Anticipate Motif Bio plc - (MTFB) to Announce -$0.96 Earnings Per Share
www.americanbankingnews.com - January 11 at 5:36 AM
 Motif Bio plc - (MTFB) Receives Average Recommendation of "Strong Buy" from Analysts Motif Bio plc - (MTFB) Receives Average Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - January 1 at 8:02 AM
Motif Bio (MTFB) Research Coverage Started at WBB SecuritiesMotif Bio (MTFB) Research Coverage Started at WBB Securities
www.americanbankingnews.com - December 29 at 4:18 PM
Motif Bios (MTFB) "Buy" Rating Reaffirmed at Seaport Global SecuritiesMotif Bio's (MTFB) "Buy" Rating Reaffirmed at Seaport Global Securities
www.americanbankingnews.com - December 28 at 7:24 AM
Motif Bio REVIVE-1 Phase 3 Study Results with Iclaprim Published in Peer-reviewed Journal, Clinical Infectious DiseasesMotif Bio REVIVE-1 Phase 3 Study Results with Iclaprim Published in Peer-reviewed Journal, Clinical Infectious Diseases
finance.yahoo.com - December 21 at 9:02 AM
 Brokerages Set $31.50 Price Target for Motif Bio plc - (MTFB) Brokerages Set $31.50 Price Target for Motif Bio plc - (MTFB)
www.americanbankingnews.com - December 15 at 5:30 AM
One ‘secret’ growth stock I’d buy alongside Motif Bio plcOne ‘secret’ growth stock I’d buy alongside Motif Bio plc
uk.finance.yahoo.com - December 6 at 5:45 PM
Zacks: Motif Bio Plc (MTFB) Given $31.50 Average Price Target by BrokeragesZacks: Motif Bio Plc (MTFB) Given $31.50 Average Price Target by Brokerages
www.americanbankingnews.com - November 24 at 11:16 AM
Zacks: Motif Bio Plc (MTFB) Given Consensus Rating of "Strong Buy" by BrokeragesZacks: Motif Bio Plc (MTFB) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 19 at 11:46 PM
Motif Bio secures up to US$20 million debt financingMotif Bio secures up to US$20 million debt financing
finance.yahoo.com - November 15 at 6:33 AM
 Motif Bio Plc (MTFB) Given $31.50 Average Target Price by Analysts Motif Bio Plc (MTFB) Given $31.50 Average Target Price by Analysts
www.americanbankingnews.com - November 3 at 2:00 PM
MTFB. Motif Bio Plc-MTFB. Motif Bio Plc-
www.lse.co.uk - October 15 at 7:48 PM
Should You Buy Motif Bio plc (AIM:MTFB) Now?Should You Buy Motif Bio plc (AIM:MTFB) Now?
finance.yahoo.com - October 13 at 7:05 AM
Motif Bio Plc (MTFB) Rating Reiterated by HC WainwrightMotif Bio Plc (MTFB) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - October 11 at 8:02 AM
MTFB: Positive Results From Second Phase 3 Study of Iclaprim; NDA Filing Anticipated in 1Q18MTFB: Positive Results From Second Phase 3 Study of Iclaprim; NDA Filing Anticipated in 1Q18
finance.yahoo.com - October 6 at 9:32 AM
HC Wainwright Raises Motif Bio Plc (MTFB) Price Target to $32.00HC Wainwright Raises Motif Bio Plc (MTFB) Price Target to $32.00
www.americanbankingnews.com - October 4 at 9:32 AM
Motif Bio reports half-year 2017 financial results and operational progressMotif Bio reports half-year 2017 financial results and operational progress
www.nasdaq.com - September 29 at 1:20 PM
Motif Bio Plcs (MTFB) Buy Rating Reaffirmed at HC WainwrightMotif Bio Plc's (MTFB) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - September 20 at 9:42 AM
Motif Bio announces iclaprim granted Orphan Drug Designation by US FDA for treatment of Staphylococcus aureus lung infections in patients with cystic fibrosisMotif Bio announces iclaprim granted Orphan Drug Designation by US FDA for treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis
finance.yahoo.com - September 16 at 6:41 AM
Motif Bio to Host Investor and Analyst Event on September 20, 2017 in New YorkMotif Bio to Host Investor and Analyst Event on September 20, 2017 in New York
finance.yahoo.com - September 9 at 6:25 AM
Motif Bio Plc (MTFB) Forecasted to Post Q2 2017 Earnings of ($0.80) Per ShareMotif Bio Plc (MTFB) Forecasted to Post Q2 2017 Earnings of ($0.80) Per Share
www.americanbankingnews.com - September 8 at 5:40 AM
MTFB: Initiating Coverage of Motif Bio Plc; Novel Antibiotic With Positive Phase 3 ResultsMTFB: Initiating Coverage of Motif Bio Plc; Novel Antibiotic With Positive Phase 3 Results
finance.yahoo.com - September 6 at 6:34 AM
Motif Bio to present at upcoming investor and scientific conferencesMotif Bio to present at upcoming investor and scientific conferences
finance.yahoo.com - September 1 at 6:06 AM
Motif Bio to Present at the 7th Annual Trout Group Hamptons CEO Roundtable Conference on August 17thMotif Bio to Present at the 7th Annual Trout Group Hamptons CEO Roundtable Conference on August 17th
finance.yahoo.com - August 15 at 2:21 AM
Motif Bio’s second Phase 3 clinical trial in ABSSSI finishes patient treatment phaseMotif Bio’s second Phase 3 clinical trial in ABSSSI finishes patient treatment phase
finance.yahoo.com - August 10 at 6:03 AM
Motif Bio to Present Three Posters at IDWeek 2017Motif Bio to Present Three Posters at IDWeek 2017
finance.yahoo.com - July 7 at 7:36 AM

SEC Filings

Motif (NASDAQ:MTFB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Motif (NASDAQ:MTFB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Motif (NASDAQ MTFB) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.